Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aee-788. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 11/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 3/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | WEE1 | P30291 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 1/20 | 1.00 |
| ▸ | NEK3 | P51956 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 1/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aee-788 SCHEMBL29973591 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL613755 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL1738023 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL29389001 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL613756 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL10259799 | 0.99 | EGFR (0.98) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93737 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93738 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL4767093 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL27585261 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025217247-A1 | TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025136346-A1 | INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4479398-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4479401-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | Amgen Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118974055-A | Quinazoline compounds as inhibitors of mutant KRAS proteins and uses thereof | 美国安进公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024229317-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-118715215-A | Quinazoline compounds as inhibitors of mutant KRAS proteins and uses thereof | 美国安进公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-117561063-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4232444-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023159087-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023159086-A1 | QUINAZOLINE COMPOUNDS AND USE THEREOF AS INHIBTORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023018809-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018810-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022232332-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232331-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |